Speaking on the above is Dr Alfred Scheidegger, PhD, Founding Partner & CEO, Nextech Invest Ltd, Switzerland. He will be presenting at Pharma Partnering & Investment World Asia 2012, part of a series of conferences at the 5th Annual BioPharma Asia Convention 2012.
Dr Alfred Scheidegger is the founder and CEO of Nextech Venture, Ltd., a globally active investment management firm based in Zurich, Switzerland. Nextech Venture manages and advises three investment funds of USD 166 million with a focus on oncology. Prior to founding Nextech Venture Ltd., Dr. Scheidegger was managing director and member of the board of the Swiss Federal Institute of Technology (ETH) Zurich, Switzerland. He served as the first managing director of the Swiss Supercomputing Center (CSCS). Before that, he managed an international drug discovery project at Ciba-Geigy (today Novartis), Japan. He is co-initiator of the first national business plan contest Venture 98. Dr. Scheidegger holds a PhD in microbiology from the University of Basel, Switzerland, and has completed a post-doctorate research fellowship in enzymology at the University of Kyoto, Japan and an executive training program at Harvard Business School, USA. Dr. Scheidegger was, among numerous other assignments, member of the board of directors of Ganymed Pharmaceuticals, Germany.
Dr Scheidegger will be speaking on the following points:
Alternative partnering models for lifescience ventures
1. Relooking at traditional partnering models: Do they still work or are there better partnership strategies
2. Examining the importance of global industry standards for life science ventures to leverage on commercial opportunities and to maximize shareholder value
3. Understanding the use of assets of life science ventures: Balancing in-house development against partnering